Theravance Biopharma Investigative Site
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Balawon, Armida
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
GPS Registry, NCT05027685: The "Global Paradise System" Registry

Recruiting
N/A
3000
Europe, RoW
The Paradise Ultrasound Renal Denervation System
ReCor Medical, Inc.
Hypertension
12/30
12/31

Download Options